Menu Search
Equities

Santen Pharmaceutical Co Ltd

4536:TYO

Santen Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,671.00
  • Today's Change7.00 / 0.42%
  • Shares traded654.70k
  • 1 Year change+23.09%
  • Beta0.6195
Data delayed at least 20 minutes, as of Nov 22 2024 03:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform4
Hold3
Sell0
Strong Sell0

Share price forecast in JPY

The 10 analysts offering 12 month price targets for Santen Pharmaceutical Co Ltd have a median target of 2,075.00, with a high estimate of 2,600.00 and a low estimate of 1,700.00. The median estimate represents a 24.70% increase from the last price of 1,664.00.
High56.3%2,600.00
Med24.7%2,075.00
Low2.2%1,700.00

Dividends in JPY

In 2024, Santen Pharmaceutical Co Ltd reported a dividend of 33.00 JPY, which represents a 3.13% increase over last year. The 9 analysts covering the company expect dividends of 34.56 JPY for the upcoming fiscal year, an increase of 4.72%.
Div growth (TTM)3.13%
More ▼

Earnings history & estimates in JPY

On Nov 07, 2024, Santen Pharmaceutical Co Ltd reported 2nd quarter 2025 earnings of 23.29 per share. This result exceeded the 21.69 consensus of the 3 analysts covering the company and under-performed last year's 2nd quarter results by 3.48%.
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+2,182.68%
Santen Pharmaceutical Co Ltd reported annual 2024 earnings of 72.59 per share on May 09, 2024.
Average growth rate+113.62%
More ▼

Revenue history & estimates in JPY

Santen Pharmaceutical Co., Ltd. had 2nd quarter 2025 revenues of 71.63m. This missed the 73.29m consensus estimate of the 4 analysts following the company. This was 1.04% below the prior year's 2nd quarter results.
Average growth rate-0.51%
Santen Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 301.97m. This was 8.22% above the prior year's results.
Average growth rate+5.76%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.